Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. They currently have a $39.00 target price on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $2.00 EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.47 EPS, Q4 2026 earnings at $0.46 EPS and FY2026 earnings at $1.68 EPS.

GMAB has been the subject of a number of other research reports. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Finally, Truist Financial reiterated a “buy” rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $39.25.

Genmab A/S Stock Down 2.2%

GMAB stock opened at $32.63 on Wednesday. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $35.43. The firm has a market capitalization of $20.96 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 19.53 and a beta of 0.90. The company has a fifty day simple moving average of $32.47 and a two-hundred day simple moving average of $29.05.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.17. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. As a group, analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alliancebernstein L.P. boosted its holdings in Genmab A/S by 2.7% during the third quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock worth $335,957,000 after buying an additional 291,538 shares in the last quarter. Orbis Allan Gray Ltd raised its position in shares of Genmab A/S by 38.7% in the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after acquiring an additional 2,209,659 shares during the period. Paradigm Biocapital Advisors LP purchased a new stake in shares of Genmab A/S during the 3rd quarter worth about $117,063,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Genmab A/S by 5.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock worth $111,735,000 after acquiring an additional 188,761 shares in the last quarter. Finally, First Trust Advisors LP grew its position in shares of Genmab A/S by 3.5% during the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock valued at $36,575,000 after acquiring an additional 60,504 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 target while raising FY2025 estimates (now $2.00 EPS) and some near‑term quarter forecasts, providing support under the stock. HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab disclosed grants of 32,806 restricted stock units and 34,307 warrants to employees — normal for biotech compensation but potentially modestly dilutive if exercised; not likely to be a major near‑term earnings driver. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short‑interest data for January appears to show no meaningful or reliable change (entries show zero/NaN), so short covering is not a clear factor in today’s move.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full‑year EPS forecasts: FY2026 now $1.68 (was $2.14); Q4 2026 to $0.46 (from $0.63); Q1 2026 to $0.27 (from $0.34); Q2 2026 to $0.49 (from $0.58); Q3 2026 to $0.47 (from $0.59). Those downgrades lower near‑term earnings visibility and are the primary reason investors are marking the stock down today.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.